Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL

By sjmartinez • October 19, 2024

Roloff GW, Aldoss I, Kopmar NE, Lin C, Dekker SE, Gupta VK, O'Connor TE, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed N, Zhang A, Miller K, Dykes KC, Ahmed M, Chen EC, Mercadal S, Schwartz M, Tracy SI, Dholaria B, Mukherjee A, Battiwalla M, Logan AC, Ladha A, Guzowski C, Hoeg RT, Hilal T, Moore J, Connor MP, Hill LC, Tsai SB, Sasine JP, Solh MM, Kota VK, Koura D, Veeraputhiran M, Leonard JT, Frey NV, Park JH, Luskin MR, Bachanova V, Galal A, Pullarkat V, Stock W, Cassaday RD, Shah BD, Faramand R, Muffly L; ROCCA Consortium. Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL. J Clin Oncol. 2024 Oct 17:JCO2400321. doi: 10.1200/JCO.24.00321. Epub ahead of print. PMID: 39418622.

Tags: Fellow, Hematology/Oncology, Publications

The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia

O'Connor TE, Lin C, Roloff GW, Zhang A, Miller K, Aldoss I, Kopmar NE, Dekker SE, Gupta VK, Jeyakumar N, Muhsen IN, Valtis Y, Ahmed[...]

Isolated Lesion of Penile Kaposi Sarcoma in an HIV-Negative Male Patient

Eeraveni A, Gates G, Singh A, Ahronowitz I. Isolated Lesion of Penile Kaposi Sarcoma in an HIV-Negative Male Patient. Cureus. 2025 Jul 21;17(7):e88451. doi: 10.7759/cureus.88451.[...]

Intermediate endpoints as surrogates for long term outcomes in breast cancer adjuvant chemotherapy trials

Blasco A, López-Tarruella S, Urruticoechea A, Carrasco E, Spera G, Martín M, Bermejo B, Chap L, Ruiz-Borrego M, Crown J, García-Saenz JA, Chan A, Guerrero-Zotano[...]